INDIANAPOLIS, June 8, 2017 /PRNewswire/ -- Eli Lilly and
Company (NYSE: LLY) will conduct a webcast on Monday, June 19, 2017, to discuss the company's
pain management portfolio, including data from three Phase 3
studies of galcanezumab, an investigational treatment for the
prevention of episodic and chronic migraine, and data from one
Phase 3 study of lasmiditan, an investigational treatment for the
acute treatment of migraine. The webcast will begin at 10 a.m. Eastern time. The Phase 3 data will also
be presented at the 59th Annual Scientific Meeting of
the American Headache Society.
Investors, media and the general public can access a live
webcast of the conference call through a link that will be posted
on Lilly's website at https://investor.lilly.com/events.cfm. A
replay will also be available on the website following the
conference call.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
http://newsroom.lilly.com/social-channels.
F-LLY
Refer to: Lauren
Zierke; lauren_zierke@lilly.com; (317) 277-6524 (Media)
Philip Johnson;
johnson_philip_l@lilly.com; (317) 655-6874 (Investors)
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lilly-announces-webcast-to-discuss-pain-management-portfolio-300471275.html
SOURCE Eli Lilly and Company